Literature DB >> 19655176

Prospective evaluation of oral mucositis in acute leukemia patients receiving chemotherapy.

Velia Ramírez-Amador1, Gabriela Anaya-Saavedra, Erick Crespo-Solís, Esther Irigoyen Camacho, Imelda González-Ramírez, Sergio Ponce-de-León.   

Abstract

PURPOSE: Knowledge of oral mucositis (OM) in patients with acute leukemia (AL) and chemotherapy (CT) has remained limited. Thus, a prospective, longitudinal study was undertaken to characterize clinical features, associated risk factors, and behavior of OM in a cohort of AL patients starting CT.
METHODS: Prospective and longitudinal study. A cohort of patients, older than 15 years of age with AL, scheduled to receive CT, was followed from March 2006 to October 2007. At baseline and three times per week, for 21 days, patients had an oral examination performed using the Oral Mucositis Assessment Scale (OMAS); also, oral pain and difficulty to swallow were recorded using a visual analog scale. Weekly, salivary flow measurements (Schirmer's test modified version) were done.
RESULTS: A cohort of 29 AL patients was followed for a median time of 21 (range, 14-53) days; 12 (41.4%) developed OM, with a mean OMAS score of 0.181 (SD +/- 0.56) and a mean peak OMAS score of 1.8 (SD +/- 0.56). The OM onset mean time was 9.8 (range, 2-20, SD +/- 6.09) days, with a mean duration of 7 (range, 3-14, SD +/- 4.15) days. OM was significantly correlated with salivary flow [rs = 0.420 (P = 0.0051)], oral pain [rs = 0.47 (P < 0.0001)], ability to swallow [rs = 0.36 (P = 0.0001)], and type of food intake [rs = 0.38 (P < 0.0001)].
CONCLUSIONS: OM is a frequent and early side effect of CT closely correlated with oral pain, difficulty to swallow, and impairment in food intake.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19655176     DOI: 10.1007/s00520-009-0708-1

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  47 in total

1.  Secretion rate from minor salivary glands in patients with malignant haematological diseases receiving chemotherapy--a pilot study.

Authors:  Johan Blomgren; Sigbritt Jansson; Stig Rödjer; Dowen Birkhed
Journal:  Swed Dent J       Date:  2002

Review 2.  Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions.

Authors:  Andrei Barasch; Douglas E Peterson
Journal:  Oral Oncol       Date:  2003-02       Impact factor: 5.337

3.  A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation.

Authors:  B J Bolwell; M Kalaycio; R Sobecks; S Andresen; E Kuczkowski; L Bernhard; R Lomax; J Kohuth; S Mendiola; L Rybicki; B Pohlman
Journal:  Bone Marrow Transplant       Date:  2002-11       Impact factor: 5.483

4.  Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation.

Authors:  S T Sonis; G Oster; H Fuchs; L Bellm; W Z Bradford; J Edelsberg; V Hayden; J Eilers; J B Epstein; F G LeVeque; C Miller; D E Peterson; M M Schubert; F K Spijkervet; M Horowitz
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

5.  Quantitative analysis of the oral complications of antileukemia chemotherapy.

Authors:  S Dreizen; K B McCredie; G P Bodey; M J Keating
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1986-12

6.  Oral mucositis in patients treated with chemotherapy for solid tumors: a retrospective analysis of 150 cases.

Authors:  J E Raber-Durlacher; N I Weijl; M Abu Saris; B de Koning; A H Zwinderman; S Osanto
Journal:  Support Care Cancer       Date:  2000-09       Impact factor: 3.603

7.  Updated clinical practice guidelines for the prevention and treatment of mucositis.

Authors:  Dorothy M Keefe; Mark M Schubert; Linda S Elting; Stephen T Sonis; Joel B Epstein; Judith E Raber-Durlacher; Cesar A Migliorati; Deborah B McGuire; Ronald D Hutchins; Douglas E Peterson
Journal:  Cancer       Date:  2007-03-01       Impact factor: 6.860

8.  The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis.

Authors:  Linda S Elting; Catherine Cooksley; Mark Chambers; Scott B Cantor; Ellen Manzullo; Edward B Rubenstein
Journal:  Cancer       Date:  2003-10-01       Impact factor: 6.860

9.  Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial.

Authors:  A Kazemian; S Kamian; M Aghili; F A Hashemi; P Haddad
Journal:  Eur J Cancer Care (Engl)       Date:  2009-03       Impact factor: 2.520

10.  Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.

Authors:  Nicole Blijlevens; Matthias Schwenkglenks; Pamela Bacon; Alessandra D'Addio; Hermann Einsele; Johan Maertens; Dietger Niederwieser; Werner Rabitsch; Ann Roosaar; Tapani Ruutu; Harry Schouten; Rebecca Stone; Samuel Vokurka; Barry Quinn; Shaun McCann
Journal:  J Clin Oncol       Date:  2008-02-11       Impact factor: 44.544

View more
  1 in total

1.  Telmisartan Modulates the Oral Mucositis Induced by 5-Fluorouracil in Hamsters.

Authors:  Maisie M Barbosa; Aurigena A de Araújo; Raimundo F de Araújo Júnior; Gerlane C B Guerra; Gerly A de Castro Brito; Renata C Leitão; Susana B Ribeiro; Emanuella de Aragão Tavares; Roseane C Vasconcelos; Vinícius B Garcia; Caroline A C X de Medeiros
Journal:  Front Physiol       Date:  2018-08-29       Impact factor: 4.566

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.